{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T10:24:26Z","timestamp":1775989466111,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.ucl.2006.06.004","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T09:28:46Z","timestamp":1168421326000},"page":"447-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Tolterodine for Treatment of Overactive Bladder"],"prefix":"10.1016","volume":"33","author":[{"given":"Jamie A.","family":"Kanofsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor W.","family":"Nitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 6A","key":"10.1016\/j.ucl.2006.06.004_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0090-4295(97)00595-5","article-title":"The overactive bladder: pharmacologic basis of drug treatment","volume":"50","author":"Andersson","year":"1997","journal-title":"Urology"},{"issue":"Suppl 2","key":"10.1016\/j.ucl.2006.06.004_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1464-410X.83.s2.3.x","article-title":"Factors involved in the success of antimuscarinic treatment","volume":"83","author":"Abrams","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2006.06.004_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00002512-199506030-00007","article-title":"Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability","volume":"6","author":"Yarker","year":"1995","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ucl.2006.06.004_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-5347(17)38459-8","article-title":"Randomized, double-blind multicenter trial on treatment of frequency, urgency, and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo","volume":"145","author":"Thuroff","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2006.06.004_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/PL00007094","article-title":"Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine","volume":"19","author":"Appell","year":"2001","journal-title":"World J Urol"},{"key":"10.1016\/j.ucl.2006.06.004_bib6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2006.06.004_bib7","first-page":"13","article-title":"The mechanism of action of tolterodine","volume":"11","author":"Nilvebrant","year":"2000","journal-title":"Rev Contemp Pharmacother"},{"key":"10.1016\/j.ucl.2006.06.004_bib8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/nau.1930140606","article-title":"Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity","volume":"14","author":"Stahl","year":"1995","journal-title":"Neurourol Urodyn"},{"issue":"Suppl 6A","key":"10.1016\/j.ucl.2006.06.004_bib9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","article-title":"Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis","volume":"50","author":"Appell","year":"1997","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ucl.2006.06.004_bib10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine,\u00a0a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"Br J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2006.06.004_bib11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s001929970003","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder","volume":"10","author":"Drutz","year":"1999","journal-title":"Int Urogyn J"},{"issue":"2","key":"10.1016\/j.ucl.2006.06.004_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00126839-200203020-00001","article-title":"Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers","volume":"3","author":"Chapple","year":"2002","journal-title":"Drugs R D"},{"key":"10.1016\/j.ucl.2006.06.004_bib13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/00912700122010528","article-title":"Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system","volume":"41","author":"Todorova","year":"2001","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ucl.2006.06.004_bib14","first-page":"289","article-title":"Tolterodine, a novel muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes","volume":"26","author":"Postlind","year":"1998","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.ucl.2006.06.004_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0009-9236(98)90104-7","article-title":"Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine","volume":"63","author":"Brynne","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ucl.2006.06.004_bib16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003495-199855060-00008","article-title":"Tolterodine","volume":"55","author":"Hills","year":"1998","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ucl.2006.06.004_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002512-200118040-00005","article-title":"Tolterodine: a review of its use in the treatment of overactive bladder","volume":"18","author":"Clemett","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ucl.2006.06.004_bib18","first-page":"287","article-title":"Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity","volume":"35","author":"Brynne","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ucl.2006.06.004_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/00912700122010113","article-title":"Food increases the bioavailability of tolterodine but not effective exposure","volume":"41","author":"Olsson","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ucl.2006.06.004_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0302-2838(01)00009-4","article-title":"Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review","volume":"41","author":"Rovner","year":"2002","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2006.06.004_bib21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-200140030-00006","article-title":"Multiple-dose pharmacokinetics of a new once-daily, extended-release tolterodine formulation versus immediate-release tolterodine","volume":"40","author":"Olsson","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.ucl.2006.06.004_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003088-200140020-00005","article-title":"Food does not influence the pharmacokinetics of a new, extended-release formulation of tolterodine for once daily treatment of patients with overactive bladder","volume":"40","author":"Olsson","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ucl.2006.06.004_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","article-title":"Tolterodine\u2014a new bladder-selective antimuscarinic agent","volume":"327","author":"Nilvebrant","year":"1997","journal-title":"Eur J Pharm"},{"key":"10.1016\/j.ucl.2006.06.004_bib24","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0024-3205(97)00057-X","article-title":"Tolterodine: a new bladder selective, muscarinic receptor antagonist: pre-clinical pharmacological and clinical data","volume":"60","author":"Nilvebrant","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.ucl.2006.06.004_bib25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-0773.1997.tb02064.x","article-title":"Antimuscarinic potency and bladder selectivity of PNU-200577, a major\u00a0metabolite of tolterodine","volume":"81","author":"Nilvebrant","year":"1997","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.ucl.2006.06.004_bib26","unstructured":"Nilvebrant L, Pahlman I, d'Argy R. Tissue distribution of tolterodine and its metabolites: low penetration into the central nervous system. Presented at the 15th Meeting of the European Association of Urology. Brussels, April 12\u201315, 2000."},{"key":"10.1016\/j.ucl.2006.06.004_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0025-6196(11)62382-3","article-title":"Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study","volume":"76","author":"Appell","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ucl.2006.06.004_bib28","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ucl.2006.06.004_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1185\/030079902125000570","article-title":"Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET)","volume":"18","author":"Sussman","year":"2002","journal-title":"Cur Med Res Opin"},{"key":"10.1016\/j.ucl.2006.06.004_bib30","doi-asserted-by":"crossref","unstructured":"Coyne KS, Matza LS, Kopp Z, et\u00a0al. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 Jan 24 [Epub ahead of print].","DOI":"10.1016\/j.eururo.2006.01.007"},{"key":"10.1016\/j.ucl.2006.06.004_bib31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014306000632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014306000632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:18:59Z","timestamp":1758806339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014306000632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0094014306000632"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2006.06.004","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolterodine for Treatment of Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2006.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}